# Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

> **NCT03836157** · PHASE2 · WITHDRAWN · sponsor: **University of Oklahoma**

## Conditions studied

- Endometrial Cancer
- Endometrial Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Clear Cell Adenocarcinoma

## Interventions

- **DRUG:** Mirvetuximab Soravtansine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03836157
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05-31
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was not initiated.
- **Last updated:** 2019-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836157, "Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03836157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*